SCS Capital Management LLC Invests $1.34 Million in Thermo Fisher Scientific Inc. $TMO

Key Points

• SCS Capital Management LLC invested approximately $1.34 million in Thermo Fisher Scientific Inc. during the first quarter, acquiring 2,699 shares.
• Institutional investors now own 89.23% of Thermo Fisher Scientific's stock as other institutions have increased their holdings significantly in the company.
• Thermo Fisher Scientific recently declared a quarterly dividend of $0.43 per share, with the ex-dividend date on September 15th.

SCS Capital Management LLC purchased a new position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 2,699 shares of the medical research company's stock, valued at approximately $1,344,000.

Other institutional investors have also recently made changes to their positions in the company. Mondrian Investment Partners LTD increased its holdings in shares of Thermo Fisher Scientific by 146.1% in the 1st quarter. Mondrian Investment Partners LTD now owns 214,506 shares of the medical research company's stock worth $106,738,000 after buying an additional 127,357 shares during the last quarter. GAMMA Investing LLC grew its holdings in shares of Thermo Fisher Scientific by 22.0% during the 1st quarter. GAMMA Investing LLC now owns 4,862 shares of the medical research company's stock valued at $2,419,000 after purchasing an additional 877 shares during the last quarter. Cetera Trust Company N.A grew its holdings in shares of Thermo Fisher Scientific by 3.3% during the 1st quarter. Cetera Trust Company N.A now owns 4,646 shares of the medical research company's stock valued at $2,312,000 after purchasing an additional 150 shares during the last quarter. Philip James Wealth Mangement LLC bought a new position in shares of Thermo Fisher Scientific during the 1st quarter valued at $268,000. Finally, Security National Bank of SO Dak grew its holdings in shares of Thermo Fisher Scientific by 0.8% during the 4th quarter. Security National Bank of SO Dak now owns 8,726 shares of the medical research company's stock valued at $4,540,000 after purchasing an additional 73 shares during the last quarter. Institutional investors own 89.23% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts recently commented on TMO shares. Wells Fargo & Company reduced their target price on shares of Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating on the stock in a report on Thursday, July 24th. Evercore ISI reduced their target price on shares of Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating on the stock in a report on Tuesday, July 8th. William Blair started coverage on shares of Thermo Fisher Scientific in a report on Monday, August 18th. They set an "outperform" rating on the stock. Barclays increased their price target on shares of Thermo Fisher Scientific from $450.00 to $490.00 and gave the company an "equal weight" rating in a research report on Thursday, July 24th. Finally, Raymond James Financial reissued an "outperform" rating and set a $535.00 price target (up previously from $525.00) on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Sixteen research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $589.38.

Thermo Fisher Scientific Stock Down 1.1%

Shares of NYSE:TMO opened at $477.03 on Thursday. The firm has a market capitalization of $180.13 billion, a P/E ratio of 27.59, a P/E/G ratio of 2.58 and a beta of 0.75. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93. The stock has a 50 day moving average price of $464.58 and a 200-day moving average price of $452.37. Thermo Fisher Scientific Inc. has a 52-week low of $385.46 and a 52-week high of $623.77.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, beating the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The company had revenue of $10.86 billion for the quarter, compared to analyst estimates of $10.68 billion. During the same period in the previous year, the company posted $5.37 earnings per share. The firm's revenue was up 2.9% on a year-over-year basis. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. As a group, equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date of this dividend is Monday, September 15th. Thermo Fisher Scientific's dividend payout ratio (DPR) is 9.95%.

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the company's stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $500.96, for a total value of $5,009,600.00. Following the sale, the chief executive officer owned 115,174 shares in the company, valued at approximately $57,697,567.04. This represents a 7.99% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CAO Joseph R. Holmes sold 385 shares of the company's stock in a transaction dated Friday, August 29th. The stock was sold at an average price of $492.63, for a total transaction of $189,662.55. Following the completion of the sale, the chief accounting officer owned 2,319 shares in the company, valued at approximately $1,142,408.97. This trade represents a 14.24% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 30,066 shares of company stock valued at $14,182,963 in the last three months. Company insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.